Researchers surveyed 392 U.S. hepatologists, gastroenterologists, endocrinologists and diabetologists. Researchers attempted to highlight the current level of understanding of NASH in the medical community.
Here’s what they found:
1. Eighty-nine percent of diabetologists/endocrinologists believe they see patients daily that are at a high risk of developing NASH.
2. Approximately 65 percent of respondents said there needs to be an increased effort to produce and distribute NASH-specific education materials.
3. Sixty percent of hepatologists and GI physicians understood ballooning/inflammation should be considered a major objective for a therapeutic NASH treatment.
4. Forty-nine percent of hepatologists/gastroenterologists understood that cardiovascular disease was a leading cause of death in non-alcoholic fatty liver disease — a precursor to NASH.
Full results were presented at the American Association for the Study of Liver Diseases’ The Liver Meeting, Oct. 20 to Oct. 24 in Washington, D.C.
More articles on gastroenterology:
Memorial Hermann Endoscopy and Surgery Center physicians to pay $1.5M+ to settle Medicare fraud allegations
PPIs included on list of drugs to ‘seriously consider deprescribing’
Olympus dives deeper into endoscopy field through product expansion, forming strategic partnerships
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.